Effect of Lidocaine in Reducing Opioids Requirement in Day Care Surgery

Efficacy of Lidocaine in Decreasing Perioperative Analgesic Opioids Requirement After Ambulatory Surgery

1. *Reduced opioid consumption
2. *Decreased pain scores
3. *Fewer opioid-related side effects
4. *Improved patient satisfaction

Study Overview

• Status: Completed
• Conditions: Pain; Post-operative Pain; Post-operative Pain Control
• Intervention / Treatment: Drug: Lidocaine 2% without vessel constrictor; Drug: Normal Saline

Detailed Description

Studies have shown that lidocaine can reduce opioid consumption by 20-50% in the perioperative period.

Studies have shown that lidocaine can reduce opioid consumption by 20-50% in the perioperative period.

By reducing opioid consumption, lidocaine can also decrease the incidence of opioid-related side effects, such as nausea, vomiting, and respiratory depression.

Lidocaine's analgesic effects can improve patient satisfaction and reduce anxiety related to pain

• Study Type: Interventional
• Enrollment (Actual): 80
• Phase: Phase 3

Contacts and Locations

Study Locations

• Pakistan
  • Sindh
    • Karachi, Sindh, Pakistan
      • Liaquat National Hospital and Medical College

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• ASA 1 and 2
• patient age between 18 and 65 years
• Patient undergoing ambulatory surgeries

Exclusion Criteria:

• Pregnant women
• Allergic to Lidocaine Patient who had fever and treated with antibiotic and steroid in last month

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Intervention group; intervention group recieve inj lidocaine	Drug: Lidocaine 2% without vessel constrictor; _Lidocaine 2% provides rapid and effective local anesthesia for minor surgical procedures, such as biopsies, excisions, and suturing.; _Pain relief_: Lidocaine 2% has been shown to provide significant pain relief in patients with acute pain, such as post-operative pain, trauma, and burns.; _Reducing pain intensity_: Lidocaine 2% has been shown to reduce pain intensity by 30-50% in various clinical studies.
Placebo Comparator: Control group; control group receive Normal saline	Drug: Normal Saline; Normal saline used is an iv fluid given for fluid replacement

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Peri-operative pain	Visual Analog pain scale to rate pain scale comprises 0 to 10 score 0 minimum to 10 Maximum	at 2 hours, 4 hours, 6 hours

Collaborators and Investigators

• Sponsor: Liaquat National Hospital & Medical College
• Investigators: Principal Investigator: Hanesh Tanwani Dr Hanesh Tanwani, Liaquat National Hospital and Medical College

Publications and helpful links

Helpful Links

• Systemic lidocaine decreased the perioperative opioid analgesic requirements but failed to reduce discharge time after ambulatory surgery Allannah McKay 1, Antje Gottschalk, Annette Ploppa, Marcel E Durieux, Danja S Groves

Study record dates

Study Major Dates

• Study Start (Actual): November 5, 2023
• Primary Completion (Actual): May 10, 2024
• Study Completion (Actual): May 10, 2024

Study Registration Dates

• First Submitted: November 30, 2024
• First Submitted That Met QC Criteria: November 30, 2024
• First Posted (Actual): December 5, 2024

Study Record Updates

• Last Update Posted (Estimated): December 10, 2024
• Last Update Submitted That Met QC Criteria: December 5, 2024
• Last Verified: December 1, 2024

More Information

Terms related to this study

• Keywords: Lidocaine; Opiods; Peri-operative pain; Decrease Opioid requirement; Ambulatory surgeries
• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Postoperative Complications; Pathologic Processes; Pain, Postoperative; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Anesthetics, Local; Anesthetics; Central Nervous System Depressants; Sensory System Agents; Anti-Arrhythmia Agents; Voltage-Gated Sodium Channel Blockers; Sodium Channel Blockers; Membrane Transport Modulators; Lidocaine
• Other Study ID Numbers: ANS-2021-192-2750

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

IPD Plan Description

*Informed consent*: Participants may not have provided informed consent for their data to be shared, which could raise ethical concerns.

Patient confidentiality*: Sharing IPD could compromise patient confidentiality and anonymity, potentially harming participants or their families.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No